Drug · Composite entry covering three agents. ChEMBL identity recorded for the first-listed agent (amphetamine, CHEMBL405, first approval 1955, black box warning). Co-listed agents: atomoxetine CHEMBL641 (first approval 2002, noradrenaline reuptake inhibitor) and amantadine CHEMBL660 (first approval 1968, NMDA receptor antagonist and influenza A M2 inhibitor). No ChEMBL mechanism record returned for amphetamine itself.
7 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Traumatic Brain Injury
Enrolment: 184 · Results not recorded
Traumatic Brain Injury
Enrolment: 45 · Results not recorded
Spinal Cord Injuries
Enrolment: 25 · Results not recorded
Disorder of Consciousness · Traumatic Brain Injury
Enrolment: 30 · Results not recorded
Traumatic Brain Injury
Enrolment: 60 · Results not recorded
Traumatic Brain Injury
Enrolment: 4 · Results not recorded
Traumatic Brain Injury
Enrolment: 0 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Bilateral frontal controlled cortical impact over medial prefrontal cortex (6.0 mm craniotomy, 5 mm flat tip, AP +3.0, ML 0.0); severe -2.5 mm at 3 m/s, moderate -1.7 mm at 2 m/s, mild -0.8 mm at 1 m/s, each 0.5 s dwell; intact sham
Injury severity produced graded, persistent deficits in attention, impulse control and task efficacy, with mild injury leaving persistent impulsivity only. Amphetamine impaired sham and TBI-resilient animals at higher doses but improved accuracy and reduced premature responding in chronically impai…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.
